AstraZeneca (AZ) Korea’s ‘Imjudo Inj.’ Has passed the first step to reimbursement listing in Korea. Also, reimbursement standards for ‘Imfinzi Inj,’ which is seeking reimbursement expansions, were set. However, these are only the first steps to reimbursement.

On the 13th, the Health Insurance Review and Assessment Service held the 8th Cancer Disease Review Committee in 2024 to deliberate on the reimbursement standards for anticancer drugs.

As a result of the deliberation, reimbursement standards were set for the new drug Imjudo Inj (tremelimumab) but not for Tecvayli Inj (teclistamab, Janssen).

Imjudo is indicated for the first-line treatment of adult patients with adv